08:43 AM | April 23, 2021 | Sian Lazell
NettaLife claims it has gained the first approval for a cannabidiol (CBD) veterinary medicine as a pharmaceutical product.
The company has secured authorization for its NettaVet 10% CBD formulation for pets in Uruguay. The product’s specific indications have not been disclosed.
NettaLife is a pet health and nutrition subsidiary of RAMM Pharma – a Canadian specialist in plant-derived cannabinoid pharmaceutical products. NettaLife obtained a license for NettaVet 10% from the Uruguayan Ministry of Agriculture, Livestock and Fisheries (MGAP).
RAMM explained NettaVet 10% is “distinctly different from other products sold commercially”, as the latter are typically food supplements or nutraceutical products that have not undergone stability, efficacy or other testing by a health agency.
RAMM Pharma Receives Federal Pharmaceutical Approval and Registration of NettaVet™ 10% CBD Formulation, a First for Veterinary Medicine
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
RAMM Pharma Receives Federal Pharmaceutical Approval and Registration of NettaVet™ 10% CBD
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.